Ligand Pharmaceuticals Incorporated

Ligand Pharmaceuticals Incorporated

LGND

$298.50

Updated: 23/09/2026, 00:33:10

Market Cap
$5.98B
Sector
Healthcare
Industry
Biotechnology
Country
US
Stock valuation chart
One-year closing share-price history for LGND
Company Profile

Ligand Pharmaceuticals Incorporated operates as a biopharmaceutical entity, primarily engaged in sourcing and advancing technologies to empower pharmaceutical companies globally in their efforts to discover and develop novel therapeutic solutions. Its diverse portfolio of commercialized products addresses a wide range of medical conditions. For hematologic malignancies, these include Kyprolis and Evomela, both targeting multiple myeloma, as well as Rylaze, a treatment for acute lymphoblastic leukemia and lymphoblastic lymphoma in both adult and pediatric patients. In the realm of infectious diseases, Ligand offers Veklury for moderate to severe COVID-19, Vaxneuvance for preventing invasive Streptococcus pneumoniae disease, and Pneumosil, a pneumococcal conjugate vaccine designed to protect children from pneumonia. Bone health solutions comprise Teriparatide injection for osteoporosis and Duavee for postmenopausal osteoporosis. Other key offerings include Zulresso, a Captisol-enabled formulation of brexanolone for postpartum depression; Nexterone, a Captisol-enabled amiodarone; and Noxafil-IV, a Captisol-enabled posaconazole for intravenous administration. The company’s comprehensive product lineup further extends to the Aziyo portfolio, featuring pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune disorders; Vivitra for breast cancer; Bryxta and Zybev for a variety of indications; and Minnebro for managing hypertension. Beyond its own commercialized products, Ligand Pharmaceuticals collaborates with partners on numerous programs currently undergoing clinical development, targeting conditions such as cancer, seizure disorders, diabetes, cardiovascular ailments, muscle wasting, hepatic and renal diseases, and various other serious illnesses. The company also directly supplies Captisol materials, a proprietary technology frequently integrated into many of its drug formulations. Established in 1987, Ligand Pharmaceuticals is headquartered in Emeryville, California.

USD
NASDAQ
CEO: Todd C. Davis
Employees: 47
https://www.ligand.com
Asset Summaries
Latest generated summaries for LGND

No summaries found.

Detailed business
Structured knowledge from the latest official annual filing.
No official annual filing has completed ingestion for this company yet. The filing worker processes major-index companies incrementally and never repeats a completed fiscal year.
Full company information
Latest profile, trading, valuation, and identifier data stored for LGND.
Share price
$298.50
Market cap
$5.98B
Exchange
NASDAQ
Currency
USD
CEO
Todd C. Davis
Employees
47
IPO date
18/11/1992
Beta
0.976
Last dividend
$0.00
Day range
$289.00 – $300.48
52-week range
$163.45 – $326.63
1-day performance
2.91%
1-year performance
82.62%
Current drawdown (1Y)
-8.61%
CIK
0000886163
CUSIP
53220K504
ISIN
US53220K5048
Created
07/12/2025, 05:03:25
Last update
23/09/2026, 00:33:10

Track Ligand Pharmaceuticals Incorporated with an AI analyst

See which prediction-market events move LGND, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.

Free forever to follow AlphaBrain’s AI strategies. No card required.

Latest Database News
News linked to LGND from your Railway `news_articles` table.